Abstract
A series of cis restricted 1,2,4-triazole analogs of combretastatin A-4 (CA-4) were designed and synthesized. The antiproliferative activity of these compounds was measured on hepatocellular carcinoma HepG2, leukemia HL-60, and breast cancer MCF-7 cell lines. The obtained results showed a substantial ability of the synthesized anilides to inhibit tumor growth. On HepG2 cells, 5o and 5r showed potent IC50 values of 0.10 and 0.04 μM, respectively. While on HL-60 cells, the IC50 values were 0.004 and 0.01 μM for 5b and 5i, respectively. The inhibitory activity of tubulin polymerization was evaluated on HepG2 cells. The anilide 5r showed a remarkable tubulin inhibition compared to CA-4. Moreover, flow cytometry studies showed that HepG2 cells treated with the most potent compounds 5b and 5r were arrested in the G2/M phase of the cell cycle. This effect was accompanied by cellular apoptosis and activation of caspase-3. Molecular modeling showed several hydrogen bonding and van der Waals interactions with several important amino acids inside the colchicine binding site of tubulin.
[Display omitted]
•New 1,2,4-triazole-3-carboxamide derivatives were designed and synthesized as potent combretastatin analogs.•In vitro antiproliferative activity was evaluated against HepG2, HL-60, and MCF-7 cell lines.•Compounds 5b, 5k, 5o, 5q, and 5r showed the highest promising anticancer activities.•Compounds 5b and 5r induced apoptosis, arrested cell cycle at G2/M phase and activated caspase-3.•Molecular modelling was carried out on the colchicine binding site of β-tubulin subunit.